MBL2 and common variable immunodeficiency: The prevalence of side effects was similar between the patient group and healthy controls with the exception of nausea, which was reported exclusively by three MBL-deficient patients, one CAPS (cryopyrin-associated periodic syndrome) patient, and one CVID patient within the first 7 days.